Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia

Yuek Ling Chai, Saima Hilal, Jenny Chong, Yan Xia Ng, Oi Wah Liew, Xin Xu, M. Kamran Ikram, Narayanaswamy Venketasubramanian, Mark Richards, Mitchell K.p. Lai, Christopher ChenMedicine 2016 · DOI

TL;DR

This study investigates Growth Differentiation Factor-15 (GDF-15) as a potential biomarker for cognitive decline, specifically linking higher GDF-15 levels to cerebrovascular disease (CeVD) and white matter hyperintensities (WMH) in individuals with cognitive impairment no dementia (CIND) and Alzheimer's disease (AD). The findings suggest GDF-15 could be a useful peripheral marker for these conditions, particularly when WMH are present.

What Problem Does This Paper Address?

Cognitive decline and dementia are significant health challenges, with vascular pathology playing a crucial role alongside neurodegenerative processes like those in Alzheimer's disease (AD). While AD is characterized by amyloid plaques and neurofibrillary tangles, cerebrovascular disease (CeVD) – encompassing issues like white matter hyperintensities (WMH), lacunar infarcts, and microbleeds – is increasingly recognized as a major contributor to cognitive impairment. Identifying reliable biomarkers that can capture the interplay between vascular health and cognitive function is essential for early detection, prognosis, and potentially therapeutic interventions. Growth Differentiation Factor-15 (GDF-15), a cytokine involved in inflammatory and tissue repair responses, has shown promise as a biomarker in various conditions, including cardiovascular disease and stroke outcomes. However, its specific association with the spectrum of cognitive impairment and its relationship with different markers of CeVD, particularly WMH, remained underexplored. This paper aims to fill this gap by examining GDF-15 levels in relation to cognitive status (no cognitive impairment, CIND, and AD) and the presence and severity of CeVD, with a particular focus on WMH.

Methods

The study employed a case-control design, recruiting participants from memory clinics and the community in Singapore. Participants were categorized into three groups: no cognitive impairment (NCI), cognitive impairment no dementia (CIND), and Alzheimer's disease (AD). All subjects underwent a comprehensive battery of assessments, including:

  • Neuropsychological Assessment: A detailed battery of tests evaluated various cognitive domains to diagnose cognitive impairment and dementia according to established criteria.
  • 3-Tesla Magnetic Resonance Imaging (3T-MRI): This was used to assess cerebrovascular disease burden. Specifically, the presence of lacunes, cortical infarcts, and white matter hyperintensities (WMH) was evaluated using standardized criteria (STRIVE for infarcts/lacunes and ARWMC for WMH). Significant CeVD was defined by the presence of cortical infarcts, or ≥2 lacunes, or confluent WMH in ≥2 brain regions.
  • Blood Biomarker Measurement: Peripheral GDF-15 levels were quantified using a quantitative sandwich immunoassay technique.

Statistical analyses involved logistic regression models to assess the association between GDF-15 levels (categorized into tertiles) and cognitive status, as well as with specific CeVD markers. These analyses were adjusted for potential confounding factors such as age, education, hypertension, diabetes, anti-inflammatory medication use, and cardiovascular disease. Sensitivity analyses were conducted by excluding participants with cardiovascular diseases to confirm the independence of the observed associations.

Datasets

The study utilized data from 324 participants recruited between August 2010 and July 2014. This cohort comprised:

  • 80 participants with no cognitive impairment (NCI)
  • 144 participants with cognitive impairment no dementia (CIND)
  • 100 participants with Alzheimer's disease (AD)

The data collected included clinical information, neuropsychological test results, 3T-MRI scans, and plasma GDF-15 levels. No new benchmark datasets were introduced.

Key Insights and Ideas

  • GDF-15 as a potential indicator of vascular contribution to cognitive decline: The study strongly suggests that elevated GDF-15 is not just a general marker of cognitive impairment but is specifically linked to the vascular component of cognitive decline, particularly WMH.
  • WMH as the key CeVD correlate: Interestingly, while GDF-15 was associated with cognitive impairment and CeVD, the strongest and most consistent association was found with white matter hyperintensities (WMH), rather than cortical infarcts or lacunes. This highlights the specific vulnerability of white matter to processes reflected by GDF-15.
  • Independence from cardiovascular disease: The robust association between GDF-15, cognitive impairment, and WMH persisted even after excluding participants with pre-existing cardiovascular diseases. This suggests that GDF-15's role in cognitive decline might be mediated through direct effects on the brain vasculature, independent of systemic cardiovascular risk factors.
  • GDF-15's potential as a peripheral biomarker: The findings propose GDF-15 as a promising peripheral biomarker that could help identify individuals at risk for or experiencing cognitive impairment driven by cerebrovascular pathology, especially WMH.

Key Results

  • Higher GDF-15 levels were significantly associated with disease groups, particularly in the presence of CeVD.
  • CIND with CeVD showed an odds ratio (OR) of 7.21 (95% CI: 2.14-24.27) for higher GDF-15.
  • AD with CeVD showed a much higher OR of 21.87 (95% CI: 2.01-237.43) for higher GDF-15.
  • Among the different CeVD markers assessed by MRI, only WMH (defined by ARWMC score ≥8) was significantly associated with higher GDF-15 levels (OR: 3.97, 95% CI: 1.79–8.83).
  • The association between GDF-15 and cognitive impairment (CIND and AD) remained significant even when stratified by the presence of significant CeVD. Specifically, the highest tertile of GDF-15 was associated with CIND with CeVD (OR: 7.21) and AD with CeVD (OR: 21.87).
  • Sensitivity analyses, excluding subjects with cardiovascular diseases, confirmed that the associations between GDF-15, cognitive impairment, and WMH were statistically significant and independent of these conditions.

Limitations and Future Work

The authors acknowledge several limitations:

  • Cross-sectional design: The study's design prevents the establishment of temporal relationships, meaning it cannot determine if elevated GDF-15 precedes cognitive decline or if it's a consequence. Longitudinal studies are needed to track GDF-15 levels over time in relation to cognitive progression.
  • Recruitment bias: The majority of cases and some controls were recruited from memory clinics, which might lead to a higher burden of CeVD in the study population, potentially limiting generalizability to the broader elderly population.
  • Small sample sizes for infarcts and lacunes: The relatively small number of participants with cortical infarcts and lacunes means the study may be underpowered to detect significant associations with these specific CeVD markers.
  • Medication confounding: While NSAID use was controlled for, other medications like statins and proton-pump inhibitors, which could potentially influence GDF-15 levels, were not fully accounted for.
  • Exclusion of VaD: The study excluded participants with vascular dementia (VaD) to focus on CeVD in AD. However, given the overlap between vascular and neurodegenerative processes, future research could explore GDF-15's role in VaD and its progression.

Future work suggested by the authors includes:

  • Investigating the precise mechanisms by which GDF-15 might contribute to or reflect cerebrovascular insults and cognitive impairment.
  • Exploring potential therapeutic strategies targeting anti-inflammatory pathways, given the role of GDF-15 in inflammation.
  • Conducting longitudinal studies to assess the prognostic and diagnostic utility of GDF-15 for cognitive decline and dementia of various etiologies.
  • Examining potential associations of GDF-15 with other biomarkers, such as brain natriuretic peptide, cardiac troponin-T, and C-reactive protein.

Summary updated

Abstract

Vascular pathology plays an important role in the development of cognitive decline and dementia. In this context, growth differentiation factor-15 (GDF-15) has been suggested to be a biomarker due to its regulatory roles in inflammatory and trophic responses during tissue injury. However, limited data exist on the associations of GDF-15 with either cerebrovascular disease (CeVD) burden or the spectrum of cognitive impairment. Therefore, we aimed to study peripheral levels of GDF-15 incognitive impairment no dementia (CIND) or Alzheimer disease (AD) subjects assessed for CeVD using a case-control cohort design, with cases recruited from memory clinics and controls from memory clinics and the community. All subjects underwent detailed neuropsychological assessment, 3-Tesla magnetic resonance imaging, and venous blood draw. Subjects were classified as CIND or AD based on clinical criteria, while significant CeVD was defined as the presence of cortical infarcts and/or 2 lacunes or more, and/or confluent white matter hyperintensities (WMHs) in 2 or more brain regions. A total of 324 subjects were included in the study, of whom 80 had no cognitive impairment, 144 CIND and 100with AD. Higher GDF-15 levels were significantly associated with disease groups, especially in the presence of CeVD, namely, CIND with CeVD (odds ratios [OR]: 7.21; 95% confidence interval [CI]: 2.14-24.27) and AD with CeVD (OR: 21.87; 95% CI: 2.01-237.43). Among the different CeVD markers, only WMH was associated with higher GDF-15 levels (OR: 3.97; 95% CI: 1.79-8.83). The associations between GDF-15 and cognitive impairment as well as with WMH remained significant after excluding subjects with cardiovascular diseases. In conclusion, we showed that increased GDF-15 may be a biomarker for CIND and AD in subjects with WMH.
BibTeX
@inproceedings{chai2016growth,
  author = {Yuek Ling Chai and Saima Hilal and Jenny Chong and Yan Xia Ng and Oi Wah Liew and Xin Xu and M. Kamran Ikram and Narayanaswamy Venketasubramanian and Mark Richards and Mitchell K.P. Lai and Christopher Chen},
  title = {{Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia}},
  booktitle = {Medicine},
  year = {2016},
  doi = {10.1097/md.0000000000004566},
}
Figure